P676: Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children@E@s psychomotor development: Insights from the DUMBO registry of GETECCU.ECCO'24Year: 2024
Authors: Palomino Pérez, L.M.(1)*;Velasco Rodríguez-Belvís, M.(1);Brenes Ruiz, Y.(2);Leo-Carnerero, E.(3);Calviño Suarez, C.(4);Rivero, M.(5);Calvo, M.(6);Arroyo, M.T.(7);Fernández-Clotet, A.(8);Pérez-Martínez, I.(9);Masedo González, Á.(10);Hernández, V.(11);Ruiz-Cerulla, A.(12);López Serrano, P.(13);Vega, P.(14);Rodríguez-Lago, I.(15);Vicente Lidón, R.(16);De Jorge, M.Á.(17);Guerra, I.(18);Arias García, L.(19);Molina Arriero, G.(20);Hervías Cruz, D.(21);Busquets, D.(22);Gutiérrez Casbas, A.(23);Van Domselaar, M.(24);Valldosera Gomis, G.(25);Vázquez Morón, J.M.(26);Piqueras Cano, M.(27);Lucendo, A.J.(28);Martín Arranz, M.D.(29);Ramírez de la Piscina, P.(30);Martínez Tirado, M.D.P.(31);Robles Alonso, V.(32);Marín Pedrosa, S.(33);Camargo Camero, R.(34);Armesto Gonzalez, E.(35);García-Salido, A.(36);Muñoz Codoceo, R.(1);Gisbert*, J.P.(2);Chaparro*, M.(2);
(1)Hospital Infantil Universitario Niño Jesús, Gastroenterology and Nutrition Unit, Madrid, Spain;(2)Hospital Universitario de La Princesa. Instituto de Investigación Sanitaria Princesa IIS-IP- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(3)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(4)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(6)Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Majadahonda, Spain;(7)Hospital Clínico Universitario Lozano Blesa. IIS Aragón y CIBERehd, Gastroenterology Unit, Zaragoza, Spain;(8)Hospital Clinic de Barcelona. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd. Institut d@E@Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Gastroenterology Unit, Barcelona, Spain;(9)Hospital Universitario Central de Asturias. Diet- Microbiota and Health Group. Instituto de Investigación Sanitaria del Principado de Asturias ISPA., Gastroenterology Unit, Oviedo, Spain;(10)Hospital Universitario 12 de octubre, Gastroenterology Unit, Madrid, Spain;(11)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(12)Hospital Universitario de Bellvitge- L@E@Hospitalet de Llobregat, Gastroenterology Unit, Barcelona, Spain;(13)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(14)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(15)Hospital Universitario de Galdakao. Biobizkaia Health Research Institute, Gastroenterology Unit, Bizkaia, Spain;(16)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(17)Hospital Universitario de Cabueñes, Gastroenterology Unit, Asturias, Spain;(18)Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(20)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(21)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(22)Hospital Trueta de Girona, Gastroenterology Unit, Girona, Spain;(23)Hospital General Universitario Dr. Balmis Alicante. ISABIAL- CIBERehd, Gastroenterology Unit, Alicante, Spain;(24)Hospital Universitario de Torrejón- Universidad Francisco de Vitoria, Gastroenterology Unit, Madrid, Spain;(25)Hospital Universitario Joan XXIII, Gastroenterology Unit, Tarragona, Spain;(26)Hospital Universitario Juan Ramón Jimenez, Gastroenterology Unit, Huelva, Spain;(27)Consorci Sanitari de Terrassa CST, Gastroenterology Unit, Barcelona, Spain;(28)Hospital General de Tomelloso. Instituto de Investigación Sanitaria La Princesa- Spain- Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Ciudad Real, Spain;(29)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(30)Hospital Universitario de Álava, Gastroenterology Unit, Álava, Spain;(31)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(32)Hospital Vall d´Hebrón, Gastroenterology Unit, Barcelona, Spain;(33)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(34)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(35)Hospital Universitario San Agustín, Gastroenterology Unit, Avilés, Spain;(36)Hospital Infantil Universitario Niño Jesús, Intensive Care Unit, Madrid, Spain;On behalf of the DUMBO project of GETECCU. *Authors share senior authorship
P677: The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD): Analysis of 40,000 Patient Years of Anti-TNF UseECCO'24Year: 2024
Authors: Al-Hillawi, L.(1,2)*;Liao, H.(3);Powell Doherty, R.(2);Bedke, N.(4);Azzu, H.(5);Cripps, S.(5);Prabhu, A.(1);White, L.(1);Ambrose, T.(1);Cheung, V.(1);Palmer, R.(1);Walsh, A.(1,2);Travis, S.(6);Ternette, N.(2,7);Brain, O.(1,2);Satsangi, J.(1,2);
(1)Oxford University Hospitals NHS Foundation Trust, Department of Gastroenterology- John Radcliffe Hospital, Oxford, United Kingdom;(2)University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom;(3)University of Oxford, Jenner Institute, Oxford, United Kingdom;(4)University of Oxford, Nuffield Department of Medicine- Center for Immuno-oncology, Oxford, United Kingdom;(5)Oxford University Hospitals NHS Foundation Trust, Pharmacy Department- John Radcliffe Hospital, Oxford, United Kingdom;(6)Kennedy Institute of Rheumatology, Biomedical Research Centre, Oxford, United Kingdom;(7)University of Oxford, Nuffield Department of Medicine - Centre for Cellular and Molecular Physiology, Oxford, United Kingdom;The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD)
P678: Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTEECCO'24Year: 2024
Authors: FeaganSenior Scientific Officer, B.G.(1,2)*;Matsuoka, K.(3);Rogler, G.(4);Laharie, D.(5);Vermeire, S.(6);Danese, S.(7,8);Loftus- Jr, E.V.(9);Beales, I.(10,11);Schreiber, S.(12);Kim, H.J.(13);Faes, M.(14);Masior, T.(15);Rudolph, C.(16);Peyrin-Biroulet, L.(17,18,19,20,21,22);
(1)Alimentiv Inc., Senior Scientific Director, London ON, Canada;(2)Western University, Division of Gastroenterology- London Health Sciences Centre, London ON, Canada;(3)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(4)University Hospital Zurich- University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;(5)Hospital Center University de Bordeaux- Magellan Medico-Surgical Center- Haut-Lévêque Hospital- University of Bordeaux- Inserm, Department of Gastroenterology, Bordeaux, France;(6)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(7)IRCCS Hospital San Raffaele, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(8)Vita-Salute San Raffaele University, Department of Gastroenterology, Milan, Italy;(9)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester MN, United States;(10)Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Gastroenterology, Norwich, United Kingdom;(11)University of East Anglia, Department of Gastroenterology, Norwich, United Kingdom;(12)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(13)College of Medicine- Kyung Hee University, Department of Internal Medicine, Seoul, Korea- Republic Of;(14)Galapagos NV, Biostatistics, Mechelen, Belgium;(15)Galapagos GmbH, Clinical Development, Basel, Switzerland;(16)Galapagos B.V., Medical Affairs, Leiden, The Netherlands;(17)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(18)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal QC, Canada;(19)Paris IBD Center, Ambroise Paré – Hartmann Private Hospital Group, Neuilly-sur-Seine, France;(20)Nancy University Hospital, FHU Curing and Preventing IMID CURE, Vandœuvre-lès-Nancy, France;(21)Nancy University Hospital, INFINY Institute, Vandœuvre-lès-Nancy, France;(22)University of Lorraine, Inserm- NGERE, Nancy, France;
P679: Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial.ECCO'24Year: 2024
Authors: Vuitton, L.(1)*;Poullenot , F.(2);Bouhnik, Y.(3);Wils, P.(4);Buisson, A.(5);Viennot, S.(6);Bouguen , G.(7);Hébuterne, X.(8);Gilletta, C.(9);Nancey, S.(10);Bourreille, A.(11);Amil, M.(12);Altwegg, R.(13);Goutorbe, F.(14);Caillo, L.(15);Plastaras, L.(16);Brixi, H.(17);Simon, M.(18);Serrero, M.(19);Fumery, M.(20);Rahier, J.F.(21);Vicaut, E.(22);Peyrin-Biroulet, L.(23);
(1)CHU Besançon, Department of Gastroenterology, Besançon, France;(2)CHU Bordeaux, Department of Gastroenterology, Bordeaux, France;(3)APHP Hopital Beaujon and Institut des MICI, Department of Gastroenterology, Neuilly and Créteil, France;(4)CHU Lille, Department of Hepatogastroenterology, Lille, France;(5)CHU Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France;(6)CHU Caen, Department of Gastroenterology, Caen and Paris, France;(7)CHU Rennes, Department of Gastroenterology, Rennes, France;(8)CHU Nice, Department of Gastroenterology, Nice, France;(9)CHU Toulouse, Department of Gastroenterology, Toulouse, France;(10)CHU Lyon Sud, Department of Gastroenterology, Lyon, France;(11)CHU Nantes, Department of Gastroenterology, Nantes, France;(12)CH La Roche Sur Yon, Department of Gastroenterology, La Roche Sur Yon, France;(13)CHU Montpellier, Department of Gastroenterology, Montpellier, France;(14)CH Bayonne, Department of Gastroenterology, Bayonne, France;(15)CHU Nimes, Department of Gastroenterology, Nimes, France;(16)CH Colmar, Department of Gastroenterology, Colmar, France;(17)CHU Reims, Department of Gastroenterology, Reims, France;(18)Institut Montsouris, Department of Gastroenterology, Paris, France;(19)APHM Hopital Nord Marseille, Department of Gastroenterology, Marseille, France;(20)CHU Amiens, Department of Gastroenterology, Amiens, France;(21)CHU Namur, Department of Gastroenterology, Namur, Belgium;(22)APHP, Methodology, Paris, France;(23)CHU Nancy, Department of Gastroenterology, Nancy, France;
P680: Comparative risk of serious infection with vedolizumab vs anti-TNF in Inflammatory Bowel Disease: Results from nationwide Swedish registersECCO'24Year: 2024
Authors: Karlqvist, S.(1)*;Sachs, M.(2,3);Eriksson, C.(1,4);Cao, Y.(5,6);Montgomery, S.(4,5,7);Ludvigsson, J.F.(3,8,9);Olén, O.(4,10);Halfvarson, J.(1);
(1)Örebro University, Department of Gastroenterology, Örebro, Sweden;(2)University of Copenhagen, Department of Public Health, Copenhagen, Denmark;(3)Karolinska Institute, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(4)Karolinska Institute, Department of Medicine Solna, Stockholm, Sweden;(5)Örebro University, Clinical Epidemiology and Biostatistics, Örebro, Sweden;(6)Institute of Environmental Medicine- Karolinska Institute, Unit of Integrative Epidemiology, Stockholm, Sweden;(7)University College London, Department of Epidemiology and Public Health, London, United Kingdom;(8)Columbia University College of Physicians and Surgeons, Department of Medicine, New York, United States;(9)Örebro University Hospital, Department of Paediatrics, Örebro, Sweden;(10)Stockholm South General Hospital, Sachs@E@ Children and Youth Hospital, Stockholm, Sweden;The SWIBREG Study Group
P681: Preliminary data from the Biologic and Partial Enteral Nutrition in Crohn’s Disease Study (BIOPIC)ECCO'24Year: 2024
Authors: White, B.(1)*;Jatkowska, A.(1);Campbell, I.(2);Brownson, E.(2);Short, B.(1);Clowe, J.(1);Seenan, J.P.(2);Gaya, D.(3);Din, S.(4);Ho, G.T.(4);Robertson, E.(5);Mowat, C.(6);Milling, S.(7);Macdonald, J.(8);Gerasimidis, K.(1);
(1)University of Glasgow, Department of Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(3)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(4)Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom;(5)University Hospital Hairmyres, Department of Gastroenterology, East Kilbride, United Kingdom;(6)Ninewells Hospital, Department of Gastroenterology, Dundee, United Kingdom;(7)University of Glasgow, School of Infection & Immunity, Glasgow, United Kingdom;(8)Queen Elizabeth Univeristy Hospital, Department of Gastroenterology, Glasgow, United Kingdom;
P682: A Retrospective Comparison of Different Treatment Modalities in Patients with Chronic PouchitisECCO'24Year: 2024
Authors: Uchitel, Y.(1)*;Cohen, N.A.(1);Hirsch, A.(1);Tulchinsky, H.(2);Zemel, M.(2);Maharshak, N.(1);
(1)Tel Aviv Medical Center, Gastroenterology, Tel Aviv, Israel;(2)Tel Aviv Medical Center, General Surgery, Tel Aviv, Israel;
P683: Economic impact of achieving mucosal healing on UC-related hospitalisations and work productivity in patients with moderately to severely active UC: A post-hoc analysis of risankizumab Phase 2b/3 trialsECCO'24Year: 2024
Authors: Peyrin-Biroulet, L.(1)*;Ungaro, R.(2);Rubin, D.T.(3);Bokemeyer, B.(4);Ricart, E.(5);Levine, P.(6);Lai, J.H.(7);Sharma, D.(6);Vladea, R.(6);Sanchez Gonzalez, Y.(6);Patel, K.(8);
(1)Department of Gastroenterology- University of Lorraine- CHRU-Nancy and University of Lorraine- Inserm- NGERE, none, Nancy, France;(2)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(3)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)Gastroenterology Practice Minden, none, Minden, Germany;(5)Inflammatory Bowel Disease Unit- Department of Gastroenterology- Hospital Clínic- IDIBAPS and Biomedical Research Networking Center in Hepatic and Digestive Diseases CIBERehd, none, Barcelona, Spain;(6)AbbVie Inc., none, North Chicago, United States;(7)AbbVie Inc. and Health Outcomes Division- College of Pharmacy- University of Texas at Austin, none, Austin, United States;(8)St George’s University Hospital, NHS Foundation Trust, London, United Kingdom;
P684: Using a pharmacokinetic simulation model to determine the optimal infliximab intensification strategy to address loss of response in inflammatory bowel diseaseECCO'24Year: 2024
Authors: Srinivasan, A.(1,2,3)*;Upton, R.(4);
(1)Austin Health, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Gastroenterology, Melbourne, Australia;(3)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(4)University of South Australia, Clinical & Health Sciences-, Adelaide, Australia;
P685: Effectiveness of a second-line anti-TNFɑ agent compared to a different mechanism of action after first anti-TNFɑ failure in ulcerative colitis: CambiaCU StudyECCO'24Year: 2024
Authors: López-Vico, M.(1)*;Hernández-Martínez, Á.(2);Soto-Escribano, P.(3);Rojas-Feria, M.(4);Cornejo-Jiménez, A.(4);Caballero-Mateos, A.M.(5);Trapero-Martínez, A.M.(6);Sánchez-Capilla, A.D.(7);Cabello-Tapia, M.J.(7);Martín-Rodríguez, M.D.M.(7);
(1)Virgen de las Nieves University Hospital, Gastroenterology and Hepatology, Granada, Spain;(2)Hospital Universitario Torrecárdenas, Gastroenterology Unit, Almería, Spain;(3)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(4)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(5)Hospital Santa Ana de Motril, Gastroenterology Unit, Motril, Spain;(6)Hospital Universitario de Jaén, Gastroenterology Unit, Jaén, Spain;(7)Hospital Universitario Virgen de la Nieves, Gastroenterology Unit, Granada, Spain;
P686: Comparison between therapeutic sequences starting with IV induction-biologic versus SC-induction biologic in bionaïve-patients with ulcerative colitis: results from the APPETISER study.ECCO'24Year: 2024
Authors: Buisson, A.(1)*;M@E@Baye, D.(1);Pereira, B.(1);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;
P687: Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a Phase 2/3 study (J-True North)ECCO'24Year: 2024
Authors: Matsuoka, K.(1)*;Nakase, H.(2);Fujii, T.(3);Hisamatsu, T.(4);Suzuki, Y.(5);Watanabe, M.(6);Uchikawa, Y.(7);Goto, S.(7);Fujimoto, G.(8);Zhang, C.(7);Hibi, T.(9);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(2)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Hokkaido, Japan;(3)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(4)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(5)Ginza Central Clinic, Gastroenterology, Tokyo, Japan;(6)Tokyo Medical and Dental University, Advanced Research Institute, Tokyo, Japan;(7)Bristol Myers Squibb K.K., Immunology- Cardiovascular & Neuroscience TA Clinical Development, Tokyo, Japan;(8)Bristol Myers Squibb K.K., Biometrics & Data Sciences, Tokyo, Japan;(9)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;
P688: Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn’s Disease After Failure of Anti-TNF Agents: Real-World EvidenceECCO'24Year: 2024
Authors: Alamer, A.(1);Al Lehaibi, L.(2);Alomar, M.(2);Aldhuwayan, F.(2);Alshouish, S.(2);Al-Ali, A.(3);Almudhry, Z.(4);Almulhim, A.(5);Althagafi, A.(6);Aldosari, S.(7);Alameel, T.(8)*;
(1)Prince Sattam Bin Abdulaziz University, Department of Clinical Pharmacy, Alkharj, Saudi Arabia;(2)Eastern Health Cluster- Dammam Medical Complex, Department of Clinical Pharmacy, Dammam, Saudi Arabia;(3)Eastern Health Cluster- Dhahran Eye Specialist Hospital, Department of Clinical Pharmacy, Dhahran, Saudi Arabia;(4)Eastern Health Cluster- Dammam Medical Complex, Department of Medicine, Dammam, Saudi Arabia;(5)King Faisal University, Department of Pharmacy Practice- College of Clinical Pharmacy, Alhofuf, Saudi Arabia;(6)King Abdulaziz University, Department of Pharmacy Practice- Faculty of Pharmacy, Jeddah, Saudi Arabia;(7)Prince Sattam Bin Abdulaziz University, Department of Clinical Pharmacy- College of Pharmacy, Alkharj, Saudi Arabia;(8)King Fahad Specialist Hospital Dammam, Department of Medicine, Dammam, Saudi Arabia;
P689: Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trialsECCO'24Year: 2024
Authors: Narula, N.(1)*;Hamam, H.(1);Wong, E.C.(1);Marshall, J.K.(1);Jairath, V.(2);Hanauer, S.B.(3);Reinisch, W.(4);Dulai, P.S.(3);
(1)McMaster University, Gastroenterology, Hamilton, Canada;(2)Western University, Gastroenterology, London, Canada;(3)Northwestern University, Gastroenterology, Chicago, United States;(4)Medical University of Vienna, Gastroenterology, Vienna, Austria;
P690: Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity.ECCO'24Year: 2024
Authors: González Antuña, J.(1)*;Valdés Delgado, T.(1);Maldonado Pérez, B.(1);Castro Laria, L.(1);Merino Bohórquez, V.(2);Calleja Hernández, M.Á.(2);Argüelles Arias, F.(1);
(1)Virgen Macarena University Hospital, Gastroenterology Department, Seville, Spain;(2)Virgen Macarena University Hospital, Pharmacy Department, Seville, Spain;
P691: Intestinal ultrasonography accuracy in the evaluation of patients with moderate to severe ulcerative colitis starting infliximab therapyECCO'24Year: 2024
Authors: Albshesh, A.(1)*;Melnik , P.(2);Dotan , A.(2);Lahat , A.(2);Ungar, B.(2);Ben-Horin, S.(2);Carter, D.(2);Kopylov , U.(2);
(1)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)Sheba Medical Center and Sackler School of Medicine- Tel-Aviv University, Department of Gastroenterology, Ramat Gan, Israel;
P692: An IBD nurse-led educational programme on safety and efficacy of adjuvated recombinant zoster vaccine can improve vaccine uptake in IBD patients on immunosuppressive treatment.ECCO'24Year: 2024
Authors: Zaetta, D.(1)*;Roncen, E.(1);Franco, M.(1);Riguccio, G.(1);Santarossa, A.(2);Buda, A.(3);De Bona, M.(1);
(1)AULSS1 Dolomiti- Gastrointestinal Inflammatory Disease Departmental Unit- S. Maria del Prato Hospital, Gastrointestinal Oncological Surgery, Feltre, Italy;(2)AULSS1 Dolomiti- Nursing Human Resources- S. Maria del Prato Hospital, Medical Direction, Feltre, Italy;(3)AULSS1 Dolomiti- Gastroenterology- S. Maria del Prato Hospital, Gastrointestinal Oncological Surgery, Feltre, Italy;
P693: Care needs and reasons for (not) seeking care among fatigued patients with Inflammatory Bowel Disease: A qualitative studyECCO'24Year: 2024
Authors: Bredero, Q.(1)*;ter Avest, M.M.(2,3,4);Fleer, J.(1);Dijkstra, G.(5);Schroevers, M.J.(1);
(1)University Medical Center Groningen, Department of Health psychology, Groningen, The Netherlands;(2)Radboud University Medical Center, Center for Mindfulness- Department of Psychiatry, Nijmegen, The Netherlands;(3)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, ‘s-Hertogenbosch, The Netherlands;(4)Radboud University, Donders Institute for Brain- Cognition and Behavior, Nijmegen, The Netherlands;(5)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;
P694: Age is a strong of predictive risk factor for anti-TNF therapy related adverse events in IBD patients.ECCO'24Year: 2024
Authors: Majumder, S.(1,2,3,4)*;Bhaduri, A.(5);Sharma, N.(4);Mohammed Nabil Quraishi, N.Q.(4);Cooney, R.(4);Ghosh, S.(1);Iacucci, M.(1,3,4,6);Shivaji, U.N.(3,4,6,7);
(1)APC Microbiome Ireland- College of Medicine and Health- University College Cork- Ireland, Medicine, Cork, Ireland;(2)NH Narayana Health- Bangalore- India, Clinical Research, Bangalore, India;(3)Institute of Immunology and Immunotherapy- University of Birmingham- UK, Immunology and Immunotherapy, Birmingham, United Kingdom;(4)University Hospitals Birmingham NHS Foundation Trust- Birmingham- UK, Gastroenterology, Birmingham, United Kingdom;(5)Dhiyo Healthcare Analytics- Bangalore, Bioinformatics, Bangalore, India;(6)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust- UK, Health Research, Birmingham, United Kingdom;(7)Mazumdar-Shaw Medical Centre- A Unit of NH Narayana Health- Bangalore- India, Gastroenterology, Bangalore, India;
P695: Untargeted proteomics analysis of baseline serum samples prior to biologic therapy initiationECCO'24Year: 2024
Authors: Rauch, M.(1)*;Laponogov, I.(2);van Welsen, I.(3);Quinn, A.(4);Joustra, V.(3);Paulich, H.(3);Camesella Perez, B.(4);Ramkisoen, R.(3);Noble, A.(4);Satsangi, J.(4);D’Haens, G.(3);Williamson, A.(1);Veselkov, K.(2);van @E@t Wout, A.(1);
(1)AlphaBiomics, Research and Development, London, United Kingdom;(2)Intelligify, Research and Development, London, United Kingdom;(3)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)University of Oxford, Nuffield Department of Experimental Medicine, Oxford, United Kingdom;